Advanced Aesthetic Technologies Announces the Treatment of the First Patient in a Pivotal Clinical Trial in China with their Algeness(R) VL Filler
Advanced Aesthetic Technologies, Inc. Announces the Treatment of the First Patient in a Pivotal Clinical Trial in China with their Algeness(R) VL (2.5% Agarose Gel) Filler for the Correction of Moderate to Severe Nasolabial Folds
PR90282
BROOKLINE, Mass., June 24, 2021 /PRNewswire=KYODO JBN/--
-- This new clinical trial is being conducted through their partnership with
Lanzhou Biotechnique Development Co., LTD (LanDev) and their parent
company China National Biotec Group Co., LTD (CNBG) and will be used to
seek marketing approval in China
Advanced Aesthetic Technologies, Inc. (AAT), a leader in aesthetic gel implant
technology, is proud to announce the initiation of a clinical trial for their
Algeness(R) VL (2.5% Agarose Gel) Filler in China in partnership with Lanzhou
Biotechnique Development Co., LTD (LanDev) and their parent company China
National Biotec Group Co., LTD (CNBG) This study aims to evaluate the
effectiveness and safety of Algeness(R) VL (2.5% agarose gel) in the treatment
of moderate to severe nasolabial folds with commercially available hyaluronic
acid fillers for injection as a control. The study will provide further
clinical evidence for the product to apply for NMPA marketing authorization in
Mainland China.
Logo - https://mma.prnewswire.com/media/1550223/AAT_Logo.jpg
Logo - https://mma.prnewswire.com/media/1550093/CNBG_Logo.jpg
According to Doug Abel, CEO of AAT, "China's aesthetics market is growing
faster than the global market. The size of the Chinese population and
relatively low market penetration of aesthetics and filler treatments in China
present enormous potential for future growth. Our novel Algeness(R) range of
dermal fillers is the first 100% natural, biocompatible and fully biodegradable
filler on the market to date, which differentiates it from other injectable
products. We are very pleased to commence the pursuit of registration in China
through our strategic partner, Lanzhou Biotechnique Development Co., LTD
(LanDev) and their parent company China National Biotec Group Co., LTD (CNBG)."
From 2015 to 2019, the global aesthetic medicine market grew steadily, with a
compound annual growth rate (CAGR) of around 8.2%. China market grew from RMB
64.8 billion in 2015 to RMB 176.9 billion in 2019 - an impressive 28.7% CAGR.
The domestic market is poised to grow at a 15.2% CAGR between 2020 and 2023
(versus 7% globally), following a period of adjustment. (1)
Wu Qiang, General Manager of Lanzhou Biotechnique Development Co. Ltd
commented, "We are proud to work with the AAT team to bring this revolutionary
injectable product to the Chinese market. We believe the distinct advantages
and high safety profile of the Algeness(R) gel filler will resonate with
aesthetic physicians and introduces a new category of biodegradable products to
our growing portfolio."
Algeness(R) is a patented family of fully resorbable injectable gel implant
dermal fillers that are 100% natural, providing advantages in terms of safety,
skin rejuvenation, and natural looking results both at rest and during facial
movement. Typical clinical advantages include minimal swelling upon injection
and immediately visible results. Algeness(R) holds a CE Mark and is currently
distributed in over 30 countries worldwide.
About Advanced Aesthetic Technologies, Inc.
AAT is a fast growing, global corporation developing new technologies for
aesthetic medicine. Our lead products, the Algeness(R) family of injectable
implants, are the culmination of more than 10 years of scientific and clinical
research and were developed with the goal of providing aesthetic injectors
advances in the ability to achieve deep structural support, clean definition,
and exceptional clinical outcomes where the result at the time of treatment is
the final outcome. Algeness(R) is a 100% natural and biodegradable filler based
on purified agarose with a differentiated clinical and safety performance
profile. AAT continuously invests in research and product development to expand
the scientific knowledge on Algeness(R) and agarose as well as in pursuit of
new and innovative technologies to enhance aesthetic medicine and expand our
product portfolio. Algeness(R) is CE Marked, has multiple additional country
level registrations, and is currently available in over 30 countries. AAT is in
the process of pursuing registration in the US through the FDA. www.algeness.com
About Lanzhou Biotechnique Development Co., LTD (LanDev) and their parent
company China National Biotec Group Co., LTD (CNBG)
China National Biotec Group Co., LTD (CNBG), founded in 1919, is a wholly owned
subsidiary of China National Pharmaceutical Group Co., Ltd., one of the world's
top 500 enterprises. As a comprehensive biopharmaceutical enterprise, CNBG has
a long history with complete product lines and large scale, integrating
scientific research, production, sales, and postgraduate training. CNBG's
product lines cover six major biological product fields, including human
vaccines, blood products, medical beauty, animal health, antibody drugs, and
medical diagnosis. www.cnbg.com.cn
Lanzhou Biotechnique Development Co., LTD (LanDev), is a leading medical and
beauty health professional company in China. Its business covers botulinum
toxin, hyaluronic acid, collagen, laser beauty equipment, etc. LanDev is the
exclusive manufacturer of botulinum toxin A (BTXA)-Hengli(R) in China that
enjoys an approximate 70% market share for BTXA in China. Hengli(R) has been
sold for more than 20 years and has accumulated more than ten million of
clinical use cases. At the same time, LanDev is the exclusive distributor in
mainland China of Princess, the hyaluronic acid fillers produced by
CROMA-Pharma GmbH, an Austrian company. LanDev has also established an indepth
strategic partnership with Cynosure, an industry leading U.S. company. LanDev
is becoming an innovative enterprise leading the development of the domestic
industry with its growing international competitiveness and social respects.
Contact: filler@algeness.com
(1)
SOURCE: Advanced Aesthetic Technologies, Inc.
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。